← All trials
NCT06542497
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2024
- Primary completion
- Oct 30, 2025
- Completion date
- May 31, 2026
- First posted
- Aug 7, 2024
- Last posted
- Aug 23, 2024
- Enrollment
- 545
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ocuphire Pharma, Inc.Lead sponsor
- Ocuphire Pharma, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.